Contraindicated (1)bortezomib will boost the degree or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may perhaps improve mavacamten systemic exposure, leading to heart failure because of systolic dysfunction. B: Could be satisfactory. Both animal reports exhibit no hazard but human experiments not https://lewisr000kwh4.life-wiki.com/user